Zucara Therapeutics doses first patient in Phase 2a ‘ZONE’ trial

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Zucara Therapeutics, a diabetes life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, recently announced that it has dosed the first patient in its Phase 2a trial of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes.

Zucara Therapeutics is an OBIO® member and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Allarta receives award from JDRF to advance its work in creating a functional cure for type 1 diabetes
Next

Paradox Immunotherapeutics is BIO’s emerging Start-Up Stadium winner